2020 consensus guideline for optimal approach to the diagnosis and treatment of HER2-positive breast cancer in Bosnia and Herzegovina

Beslija, S.; Gojkovic, Zdenka; Cerić, Timur; Abazović, Alma Mekić; Marijanović, Inga; Vranić, Semir; Mustedanagić-Mujanović, Jasminka; Skenderi, Faruk; Rakita, Ivanka; Guzijan, Aleksandar; Koprić, Dijana; Humačkić, Alen; Trokić, Danijela; Alidžanović, Jasmina; Efendić, Alma; Šišić, Ibrahim; Drljević, Harun; Beslagic, Vanesa; Babić, Božana; Pašić, Azra; Ramić, Anela; Mikić, Dijana; Guzin, Zlatko; Karan, Dragana; Buhovac, Teo; Miletić, Dragana; Šečić, Senad; Šahmić, Azra Đozić; Mujbegović, Lejla; Kubura, Alisa; Burina, Mensura; Lalović, Nenad; Đukić, Nikolina; Mašić, Jelena Vladičić; Ćuk, Mirjana; Stanušić, Rajna

doi:10.17305/bjbms.2020.4846

Cited by 3 publications

(1 citation statement)

References 21 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dual therapy (trastuzumab-pertuzumab) in addition to chemotherapy is the criterion standard for the first-line treatment of HER2-positive mBC. Trastuzumab emtansine (T-DM1) is the recommended therapy for HER2-positive mBC in second-line treatment [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Differences in Outcomes Between Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer Patients in Upper Middle-Income versus High-Income Countries: A Retrospective Study from 4 Oncology Centers

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background Therapeutic options for human epidermal growth factor 2 (HER2)-positive metastatic breast cancer (mBC) are developing rapidly. This study aimed to determine the differences in the survival outcomes of patients with HER2-positive mBC in relation to access to anti-HER therapy at 3 oncology centers in upper-middle-income countries (UMICs) and 1 oncology center in a high-income country (HIC). Material/Methods We retrospectively identified 42 patients from Croatia (HIC), 71 patients from Serbia (UMIC), and 57 from Bosnia and Herzegovina (UMIC) diagnosed with HER2-positive mBC who were treated between January 2015 and December 2020. The pathohistological features of the tumors were obtained from the pathological findings, which were made according to standard procedures for each center. Patients were treated depending on the availability of therapy, which differed for centers in different countries. We evaluated disease-free survival, progression-free survival, and overall survival (OS) based on the availability of first- and second-line anti-HER2 therapy in UMICs vs HIC. Results OS in first-line therapy was better in patients treated with dual HER2 blockade than in patients treated without dual HER2 blockade, P <0.001. OS in second-line therapy was significantly better in patients treated with trastuzumab emtansine than in patients treated with other reported regimens, P =0.004. Conclusions Results of our study showed superior survival among patients who were treated with dual first-line HER2 therapy as well as second-line trastuzumab emtansine therapy than in those patients in other centers where these drugs were not available. Raising awareness about this could help improve the situation.

show abstract

Section: Introductionmentioning

confidence: 99%

Differences in Outcomes Between Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer Patients in Upper Middle-Income versus High-Income Countries: A Retrospective Study from 4 Oncology Centers

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

Guidelines for breast cancer treatment in Bosnia and Herzegovina

Hadžikadić-Gušić

Cerić

Marijanović³

et al. 2022

Bosn J of Basic Med Sci

View full text Add to dashboard Cite

Breast cancer is the most common cancer among women. In Bosnia and Herzegovina, accurate data on the status of breast cancer are lacking due to the absence of a central registry. Multiple international guidelines imply that institutions that monitor breast cancer patients should have optimal therapeutic options for treatment. In addition, there have been several international consensus guidelines written on the management of breast cancer. Application of consensus guidelines have previously been demonstrated to have a positive influence on breast cancer care. The importance of specialty breast centers has previously been reported. As part of the 2021 Bosnian-Hercegovinian American Academy of Arts and Sciences (BHAAAS) conference in Mostar, a round table of multidisciplinary specialists from Bosnia and Herzegovina and the diaspora was held. All were either members of BHAAAS or regularly participate in collaborative projects. The focus of the consortium was to write the first multidisciplinary guidelines for the general management of breast cancer in Bosnia and Herzegovina. The grading system used is reported in Table 1. Statements without use of a grading system were considered standard clinical practice by our panel of experts (see Table 2). Guidelines were developed for each area of breast cancer treatment and management. These guidelines will serve as a resource for practitioners managing breast cancer in the Bosnia and Hercegovina region. This might also be of benefit to the ministry of health and any future investors interested in developing breast cancer care policies in this region of the world.

show abstract

A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast Cancer

Alasmari

2022

Cancers

View full text Add to dashboard Cite

Breast cancer (BC) is the most commonly diagnosed cancer globally, with high mortality rates. Targeted drug therapies have revolutionized cancer treatment. For example, treatment with human epidermal receptor 2 (HER2) antagonists has markedly improved the prognosis of patients with HER2-positive BC (HER2 + BC). However, HER2+ metastatic BC (MBC) remains prevalent owing to its resistance to conventional anti-HER2 drugs. Therefore, novel agents are needed to overcome the limitations of existing cancer treatments and to enhance the progression-free and overall survival rates. Progress has been made by optimizing the fragment crystallizable (Fc) domain of trastuzumab, an IgG1 monoclonal, chimeric anti-HER2 antibody, to develop margetuximab. The modified Fc domain of margetuximab enhances its binding affinity to CD16A and decreases its binding affinity to CD32B, thereby promoting its antitumor activity. This review summarizes studies on the efficacy of margetuximab, discusses its utility as an anti-HER2 monoclonal antibody drug for the treatment of HER2+BC, and presents the latest advances in the treatment of BC. This review provides insights into the clinical implication of margetuximab in HER2 + MBC treatment.

show abstract

2020 consensus guideline for optimal approach to the diagnosis and treatment of HER2-positive breast cancer in Bosnia and Herzegovina

Cited by 3 publications

References 21 publications

Differences in Outcomes Between Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer Patients in Upper Middle-Income versus High-Income Countries: A Retrospective Study from 4 Oncology Centers

Differences in Outcomes Between Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer Patients in Upper Middle-Income versus High-Income Countries: A Retrospective Study from 4 Oncology Centers

Guidelines for breast cancer treatment in Bosnia and Herzegovina

A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast Cancer

Contact Info

Product

Resources

About